Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Oct 8, 2015; 7(22): 2363-2368
Published online Oct 8, 2015. doi: 10.4254/wjh.v7.i22.2363
Published online Oct 8, 2015. doi: 10.4254/wjh.v7.i22.2363
All-oral interferon-free treatments: The end of hepatitis C virus story, the dream and the reality
Luigi E Adinolfi, Barbara Guerrera, Department of Medical, Surgical, Neurological, Geriatric and Metabolic Sciences, Second University of Naples, 80100 Naples, Italy
Author contributions: Adinolfi LE and Guerrera B conceive and wrote the paper.
Conflict-of-interest statement: The authors do not have conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Luigi E Adinolfi, MD, Professor, Director, Department of Medical, Surgical, Neurological, Geriatric and Metabolic Sciences, Second University of Naples, ASL Caserta, Rione Santella, 80100 Naples, Italy. luigielio.adinolfi@unina2.it
Telephone: +39-823-690642 Fax: +39-823-690642
Received: May 27, 2015
Peer-review started: May 28, 2015
First decision: July 27, 2015
Revised: August 14, 2015
Accepted: September 16, 2015
Article in press: September 18, 2015
Published online: October 8, 2015
Peer-review started: May 28, 2015
First decision: July 27, 2015
Revised: August 14, 2015
Accepted: September 16, 2015
Article in press: September 18, 2015
Published online: October 8, 2015
Core Tip
Core tip: It is begun the era of all-oral direct-acting antiviral drugs for hepatitis C virus (HCV) treatment allowing interferon-free therapeutic regimens. These regimens are safe and yield cure rate greater than 90%. The therapeutic success has posed the basis for HCV elimination, although, confirmation are waiting from real world. However, many conditions hinder the fulfillment of the dream. These conditions are the excessive cost of drugs, the access and delivery of care, the epidemiology of HCV and the political commitments. Thus, an urgent effort must be done to make accessible on large-scale all-oral anti-HCV therapies allowing saving millions of lives.